### 1

Framing we agree except

1. **Moral uncertainty means preventing extinction should be our highest priority.  
   Bostrom 12** [Nick Bostrom. Faculty of Philosophy & Oxford Martin School University of Oxford. “Existential Risk Prevention as Global Priority.” Global Policy (2012)]  
   These reflections on **moral uncertainty suggest** an alternative, complementary way of looking at existential risk; they also suggest a new way of thinking about the ideal of sustainability. Let me elaborate.¶ **Our present understanding of axiology might** well **be confused. We may not** nowknow — at least not in concrete detail — what outcomes would count as a big win for humanity; we might not even yet **be able to imagine the best ends** of our journey. **If we are** indeedprofoundly **uncertain** about our ultimate aims,then we should recognize that **there is a great** option **value in preserving** — and ideally improving — **our ability to recognize value and** to **steer the future accordingly. Ensuring** that **there will be a future** version of **humanity** with great powers and a propensity to use them wisely **is** plausibly **the best way** available to us **to increase the probability that the future will contain** a lot of **value.** To do this, we must prevent any existential catastrophe.

### 2

Perm do both : abolish wto gets rid of trips lack of comp

Perm do cp: ipp not in cp, j doing the aff

**Text: The World Trade Organization ought to be abolished. The United States ought to independently and without influence from international government reduce IP protection for COVID-19**

**Hawley, senator, JD Yale, 20**

(Josh, 5-5, https://www.nytimes.com/2020/05/05/opinion/hawley-abolish-wto-china.html)

The coronavirus emergency is not only a public health crisis. With [30 million Americans unemployed](https://www.cnbc.com/2020/04/30/us-weekly-jobless-claims.html), it is also an economic crisis. And it has exposed a hard truth about the modern global economy: it weakens American workers and has empowered China’s rise. That must change. The global economic system as we know it is a relic; it requires reform, top to bottom. We should begin with one of its leading institutions, **the World Trade Organization. We should abolish it.**

**Eliminating the WTO ends U.S. global hegemony**

**Bello, PhD, 2000**

(Walden, Sociology @ Stanford, https://users.ox.ac.uk/~magd1352/ecologist/Should%20WTO%20be%20abolished.pdf)

The idea that the world needs the World Trade Organisation (WTO) is one of the biggest lies of our time. The WTO came about, in 1995, mainly because it was in the interest of the US and its corporations. The European Union, Japan and especially the developing countries were mostly ambivalent about the idea; it was the US which drove it on. Why? Because though the US, back in 1948, blocked the formation of an International Trade Organisation (ITO), believing that, at that time, the interests of its corporations would not be served by such a global body, it had changed its mind by the 1990s. Now it wanted an international trade body. Why? Because its global economic dominance was threatened. The flexible GATT (General Agreement on Tariffs and Trade) system, which preceded the WTO, had allowed the emergence of Europe and East Asia as competing industrial centres that threatened US dominance even in many high-tech industries. Under GATT’s system of global agricultural trade, Europe had emerged as a formidable agricultural power even as Third World governments concerned with preserving their agriculture and rural societies limited the penetration of their markets by US agricultural products. In other words, before the WTO, **global trade was growing by leaps and bounds**, but countries were using trade policy to industrialise and adapt to the growth of trade so that their economies would be enhanced by global trade and not be marginalised by it. That was a problem, from the US point of view. And that was why the US needed the WTO. The essence of the WTO is seen in three of its central agreements: the Agreement on Trade Related Intellectual Property Rights (TRIPs), the Agreement on Agriculture (AOA), and the Agreement on Trade Related Investment Measures (TRIMs). The purpose of TRIPs is **not to promote free trade but to enhance monopoly power**. One cannot quarrel with the fact that innovators should have preferential access to the benefits that flow from their innovation for a period of time. TRIPs, however, goes beyond this to institutionalise a monopoly for high-tech corporate innovators, most of them from the North. Among other things, TRIPs provides a generalised minimum patent protection of 20 years; institutes draconian border regulations against products judged to be violating intellectual property rights; and – contrary to the judicial principle of presuming innocence until proven guilty – places the burden of proof on the presumed violator of process patents. What TRIPs does is reinforce the monopolistic or oligopolistic position of US high tech firms such as Microsoft and Intel. It makes industrialisation by imitation or industrialisation via loose conditions of technology transfer – a strategy employed by the US, Germany, Japan, and South Korea during the early phases of their industrialisation – all but impossible. It enables **the technological leader**, in this case **the US, to greatly influence** **the pace of technological and industrial development in the rest of the world**.

**Primacy causes endless war, terror, authoritarianism, prolif, and Russia-China aggression.**

**Ashford, PhD, 19**

(Emma, PoliSci@UVA, Fellow@CATO, Power and Pragmatism: Reforming American Foreign Policy for the 21st Century, in New Voices in Grand Strategy, 4, CNAS)

**Humility is a virtue**. Yet in the last quarter century, American policymakers have been far more likely to embrace the notion of America as the “indispensable nation,” responsible for protecting allies, promoting democracy and human rights, tamping down conflicts, and generally managing global affairs. Compare this ideal to the U.S. track record – **endless Middle Eastern wars, the rise of ISIS, global democratic backsliding, a revanchist Russia, resurgent China**, and a world reeling from the election of President Donald Trump – and this label seems instead **the height of hubris.** Many of the failures of U.S. foreign policy speak for themselves. As the daily drumbeat of bad news attests, interventions in Iraq and Libya were **not victories for human rights or democracy, but rather massively destabilizing** for the Middle East as a whole. Afghanistan – despite initial military successes – has become a quagmire, highlighting the futility of nation- building. Other failures of America’s grand strategy are less visible, but no less damaging. NATO expansion into Eastern Europe helped to reignite hostility between Russia and the West. Worse, it has diluted the alliance’s defensive capacity and its democratic character. And even as the war on terror fades from public view, it remains as open-ended as ever: Today, the United States is **at war in seven countries and engaged in “combating terrorism’ in more than 80**.1 To put it bluntly: America’s strategy since the end of the Cold War – **whether it is called primacy or liberal internationalism** – may not be a total failure, but it **has not been successful** either. Many have tried to place blame for these poor outcomes.2 But recrimination is less important than understanding why America’s strategy has failed so badly and avoiding these mistakes in future. Much of the explanation is the natural outcome of changing constraints. **Iraq and Libya should not be viewed as regrettable anomalies, but rather the logical outcome of unipolarity and America’s liberal internationalist inclination to solve every global problem.** It’s also a reliance on **flawed assumptions** – that what is good for America is always good for the world, for example. Support for dangerous sovereignty-undermining norms adds to the problem; just look at the Responsibility to Protect (R2P), which has proved not to protect populations or stabilize fragile states, but to **provoke chaos, encourage nuclear proliferation, and undermine the international institutions.** Perhaps, if nothing else had changed, a form of watered-down liberal internationalism that foreswore interventionism and drew back from the war on terror might have been possible.3 But international politics are undergoing a period of profound transformation, from unipolarity to regional or even global multipolarity. **Primacy** – and the consistent drumbeat of calls in Washington to do more, always and everywhere – **is neither sustainable nor prudent.** Nor can we fall back on warmed-over Cold War–era strategies better suited to an era of bipolar superpower competition.

#### Empirics confirm the WTO causes conflict --- it limits options for states to take action against others, which escalates tensions by cutting off avenues for bargaining and conflict resolution

Chatagnier and Lim 16 J. Tyson Chatagnier and Haeyong Lim, Professors of Political Science at the University of Houston, “Does the WTO Exacerbate International Conflict?” Texas Triangle. 2016. http://texastriangle.weebly.com/uploads/2/5/2/4/25249202/chatagnier\_lim\_wto\_conflict.pdf

While there has been significant empirical work on issue linkage in other areas (e.g., Davis 2004; Long and Leeds 2006; Poast 2012, 2013), there is relatively little work on the pacifying effect of issue linkage (but see Wiegand 2009). One reason might be that coding is quite demanding, and that, unlike formal alliances or trade deals, international agreements over conflict are rarely well documented.1 Nonetheless, the theoretical literature suggests that there should be a negative relationship between the ability to link issues together and the likelihood of dyadic conflict. We provide an indirect test of this hypothesis below. The GATT and the WTO In the wake of the devastation of two world wars, American and European governments looked for ways to bring about peace and prosperity in the international system. Amid fears that the destabilization of the Great Depression had been precipitated by protectionist trade policies, leaders sought to establish an institution that could facilitate trade liberalization and end trade wars. To 1This may be why Wiegand’s study—which is qualitative in nature—is one of the few that attempts to examine issue linkage directly. 5 this end, in 1947, they created the GATT. The GATT was a multilateral agreement between states (23, initially, but more than 100 by the time it was subsumed by the WTO) to reduce tariffs and other trade barriers substantially and to eliminate preferential treatment among signatories. The institution provided states with a set of agreed-upon rules, as well as a forum for negotiation, facilitating cooperation among members. When one member state believed that another was in violation of the agreement, it could invoke provisions in Articles XXII and XXIII of the agreement that called for consultation and dispute settlement. While this allowed parties to form an investigative panel to assess and resolve the dispute, Zangl (2008) points out three major obstacles to settlement: panel composition was determined by the disputants (Jackson 1997); panel reports were the result of political negotiation, rather than legal decisions (Zangl 2008); and both empanelment (Hudec 1993) and sanctions (Rosendorff 2005) required unanimous approval, meaning that the defendant ultimately held veto power. Such a system is ultimately predicated on compromise and the negotiation of self-enforcing agreements. Under GATT, aggrieved parties had no recourse but to persuade violators to alter their behavior. With the establishment of the WTO, the aforementioned problems—along with a host of other issues—were resolved. The dispute settlement mechanism (DSM) under the WTO is highly legalized, with independent judicial bodies that are charged with rendering verdicts and authorizing sanctions (Goldstein and Martin 2000; Rosendorff 2005). Under the present system, complainants have significantly increased power, and they are no longer restricted to negotiating in order to convince defendants to comply with the rules.2 For this reason, it should be unsurprising that compliance has generally increased following the judicialization of the institution (Jackson 1997; Zangl 2008). The move from the GATT framework to the WTO undoubtedly deepened the institutionalization of the trade agreement, binding its member states more tightly. Kant’s (2007 [1795]) idea of a “federation of free states” dealt primarily with the imposition of law and order upon the anarchic international system. By increasing the institution’s degree of legalization, the trade organization 2Of course, negotiation still occurs within the WTO DSM. However, disputants do so in the shadow of the panel, significantly increasing the complainant’s bargaining leverage (Poletti, De Bièvre and Chatagnier 2015). 6 brought itself closer to the Kantian ideal.3 Indeed, while the GATT satisfies only the second and fourth roles of an IGO listed above (to some extent), the WTO quite clearly fulfills all four. From this perspective, we would expect the more heavily-institutionalized WTO to reduce conflict among member states to a greater degree than its predecessor. Hypothesis 1. The establishment of the WTO reduced the instances of militarized conflict among member states. At the same time, the increase in the organization’s power has limited the actions of the constituent actors. WTO members are required to behave in a non-discriminatory manner and to abide by agreed-upon standards. Failure to comply with these rules can lead to sanctions. While many of these behaviors were prohibited under the GATT as well, the much more credible threat of punishment likely reduces a state’s economic toolkit to a greater degree. If the U.S. believes, for example, that Chinese currency manipulation is adversely affecting trade, it cannot retaliate with tariffs or import quotas without a favorable ruling from the DSM. To do otherwise would be to invite sanctions against itself. Moreover, states are stripped of a range of options that could “sweeten the deal” in negotiations. A state that attempted to offer favorable terms of trade in exchange for concessions on a different dimension would be unable to do so without offering the same terms to all other trading partners; a state that offered to rein in a trade violation would have no leverage as the opponent could appeal to the DSM to have the trade-distorting measure removed. Thus, states are left with fewer options for issue-linkage in bargaining scenarios, which suggests an opposing hypothesis.

#### Interdependence doesn’t solve war – prefer studies at the multilateral not just dyadic level – competitive dynamics outweigh conflict dampening incentives.

Chatagnier and Kavakli 17 – (2017, J. Tyson, PhD in Political Science, Assistant Professor in the Department of Political Science at the University of Houston, and Kerim Can, PhD in Political Science, assistant professor at the Faculty of Arts and Social Sciences at Sabanci University in Turkey, “From Economic Competition to Military Combat: Export Similarity and International Conflict,” Journal of Conflict Resolution, Vol 61, Issue 7, 2017)

International trade has long been thought to facilitate peace among nations (Kant [1795] 1970). A voluntary exchange of goods that leaves both parties better off inherently raises the value of each side to the other, increasing the cost of conflict. The belief that economic interaction can ignite a positive dynamic of cooperation and reduce conflictual behavior is so intuitive and widespread that some political pundits have even heralded free trade as the path to world peace (see, e.g., Griswold 1998; Boudreaux 2006).The conventional wisdom within the international relations literature (e.g., Oneal and Russett 1997; Gartzke, Li, and Boehmer 2003; Polachek and Xiang 2010) reinforces these claims, having found consistent empirical (and theoretical) links between trade and peace. At the same time, however, there is certainly evidence that trade can exacerbate rivalry and conflict between states. Throughout history, states have fought their competitors for advantage (i.e., access to inputs and markets) in the global marketplace. For instance, in his authoritative account of the Anglo-German rivalry before World War I, Kennedy (1980, 464) concludes that “the most profound cause [of the conflict], surely, was economic”. More specifically, the cause was “the detectable increase in Anglo-German trade rivalry since Bismarck’s time as the latter country steadily became more competitive.” Moreover, while modern empirical international relations research has largely come down on the side of the neoliberals, it has not been monolithic. Indeed, numerous studies by Barbieri (1996, 2002) have demonstrated that increased trade actually has the potential to aggravate tensions between states. These inconsistencies in both the historical and analytical records raise questions about the simplicity of the link between trade and conflict. Additionally, the vast majority of previous work considers only the bilateral effects of trade, neglecting the way in which trade between two actors can affect a third. We remedy this oversight by analyzing the effects of trade competition, arguing that the tension produced by export competition can be an important source of international conflict. More specifically, we highlight that economic actors who face foreign competition have an incentive to use military power to gain an advantage in international markets. These domestic actors can use their economic power to influence their nation’s political elites and increase the likelihood that economic conflict erupts into war. We support this theoretical argument with several well-established historical cases including the seventeenth-century Dutch-English commercial rivalry, the pre-World War I Anglo-German rivalry, and the 1990 invasion of Kuwait by Iraq. Our argument suggests that, although trade can have a pacifying direct effect at the dyadic level, it also has strong indirect effects, which can be conflict aggravating. We test this argument using commodity-level trade data from 1962 to 2000. We measure each country pair’s portfolio similarity along nearly 1,300 commodity categories and test the effect of this variable on several indicators of international conflict. Our results strongly support our claim that countries that produce and export similar goods are significantly more likely to fight, even taking into account their bilateral trade. These findings are robust to several checks on model specification as well as alternative explanations. We also show that our findings are not driven by oil or other strategic resources and that they hold for both raw and manufactured goods. In light of these results, we are confident that we have identified a significant and practically important cause of war.

### 3

**COVID vaccine debate will kill the WTO, but the aff reverses that instability.**

**Meyer 6-18-21** (David, Senior Writer, https://fortune.com/2021/06/18/wto-covid-vaccines-patents-waiver-south-africa-trips/)

The World Trade Organization **knows all about crises**. Former U.S. President Donald Trump threw a wrench into its core function of resolving trade disputes—a blocker that President Joe Biden has not yet removed—and there is widespread dissatisfaction over the **fairness of the global trade rulebook**. The 164-country organization, under the fresh leadership of Nigeria's Ngozi Okonjo-Iweala, has a lot to fix. However, **one crisis is more pressing than the others**: **the battle over COVID-19 vaccines**, and whether the protection of their patents and other intellectual property should be temporarily lifted to boost production and end the pandemic sooner rather than later. According to some of those pushing for the waiver—which was originally proposed last year by India and South Africa—**the WTO's future rests on what happens next.** "The credibility of the WTO will depend on its ability to find a meaningful outcome on this issue that truly ramps-up and diversifies production," says Xolelwa Mlumbi-Peter, South Africa's ambassador to the WTO. "Final nail in the coffin" The Geneva-based WTO isn't an organization with power, as such—it's a framework within which countries make big decisions about trade, generally by consensus. It's supposed to be the forum where disputes get settled, because all its members have signed up to the same rules. And one of its most important rulebooks is the Agreement on Trade-Related Aspects of Intellectual Property Rights, or TRIPS, which sprang to life alongside the WTO in 1995. The WTO's founding agreement allows for rules to be waived in exceptional circumstances, and indeed this has happened before: its members agreed in 2003 to waive TRIPS obligations that were blocking the importation of cheap, generic drugs into developing countries that lack manufacturing capacity. (That waiver was effectively made permanent in 2017.) Consensus is the key here. Although the failure to reach consensus on a waiver could be overcome with a 75% supermajority vote by the WTO's membership, this would be an **unprecedented and seismic event**. In the case of the COVID-19 vaccine IP waiver, it would mean standing up to the European Union, and Germany in particular, as well as countries such as Canada and the U.K.—the U.S. recently flipped from opposing the idea of a waiver to supporting it, as did France. It's a dispute between countries, but the result will be on the WTO as a whole, say waiver advocates. "If, in the face of one of humanity's greatest challenges in a century, the WTO functionally becomes an obstacle as in contrast to part of the solution, I think **it could be the final nail in the coffin**" for the organization, says Lori Wallach, the founder of Public Citizen's Global Trade Watch, a U.S. campaigning group that focuses on the WTO and trade agreements. "If the TRIPS waiver is successful, and people see the WTO as being **part of the solution**—saving lives and livelihoods—it could **create** **goodwill and momentum to address what are still daunting structural problems**." Those problems are legion. Reform needs Top of the list is the WTO's Appellate Body, which hears appeals in members' trade disputes. It's a pivotal part of the international trade system, but Trump—incensed at decisions taken against the U.S. —blocked appointments to its seven-strong panel as judges retired. The body became completely paralyzed at the end of 2019, when two judges' terms ended and the panel no longer had the three-judge quorum it needs to rule on appeals. Anyone who hoped the advent of the Biden administration would change matters was disappointed earlier this year when the U.S. rejected a European proposal to fill the vacancies. "The United States continues to have systemic concerns with the appellate body," it said. "As members know, the United States has raised and explained its systemic concerns for more than 16 years and across multiple U.S. administrations." At her confirmation hearing in February, current U.S. Trade Representative Katherine Tai reiterated those concerns—she said the appellate body had "overstepped its authority and erred in interpreting WTO agreements in a number of cases, to the detriment of the United States and other WTO members," and accused it of dragging its heels in settling disputes. "Reforms are needed to ensure that the underlying causes of such problems do not resurface," Tai said. "While the U.S. [has] been engaging [with the WTO] it hasn't indicated it would move quickly on allowing appointments to the Appellate Body," says Bryan Mercurio, an economic-law professor at the Chinese University of Hong Kong, who opposes the vaccine waiver. "This is not a good sign. In terms of WTO governance, it's a much more important step than supporting negotiations on an [intellectual property] waiver." It's not just the U.S. that wants to see reform at the WTO. In a major policy document published in February, the EU said negotiations had failed to modernize the organization's rules, the dispute-resolution system was broken, the monitoring of countries' trade policies was ineffective, and—crucially—"the trade relationship between the U.S. and China, two of the three largest WTO members, is currently largely managed outside WTO disciplines." China is one of the key problems here. It became a WTO member in 2001 but, although this entailed significant liberalization of the Chinese economy, it did not become a full market economy. As the European Commission put it in February: "The level at which China has opened its markets does not correspond to its weight in the global economy, and the state continues to exert a decisive influence on China's economic environment with consequent competitive distortions that cannot be sufficiently addressed by current WTO rules." "China is operating from what it sees as a position of strength, so it will not be bullied into agreeing to changes which it sees as not in its interests," says Mercurio. China is at loggerheads with the U.S., the EU and others over numerous trade-related issues. Its rivals don't like its policy of demanding that Chinese citizens' data is stored on Chinese soil, nor do they approve of how foreign investors often have to partner with Chinese firms to access the country's market, in a way that leads to the transfer of technological knowhow. They also oppose China's industrial subsidies. Mercurio thinks China may agree to reforms on some of these issues, particularly regarding subsidies, but "only if it is offered something in return." All these problems won't go away if the WTO manages to come up with a TRIPS waiver for COVID-19 vaccines and medical supplies, Wallach concedes. "But," she adds, "**the will and the good faith** to tackle these challenges is **increased enormously** if the WTO has the **experience of being part of the solution, not just an obstacle."** Wallach points to a statement released earlier this month by Asia Pacific Economic Cooperation (APEC) trade ministers, which called for urgent discussions on the waiver. "The WTO must **demonstrate that global trade rules can help address the human catastrophe** of the COVID-19 pandemic and facilitate the recovery," the statement read in its section about WTO reform. Okonjo-Iweala's role The WTO's new director general, whose route to the top was unblocked in early 2021 with the demise of the Trump administration, is certainly keen to fix the problems that contributed to the early departure of her predecessor, Brazil's Robert Azevedo. "We must act now to get all our ambassadors to the table to negotiate a text" on the issue of an IP waiver for COVID vaccines, Ngozi Okonjo-Iweala, director general of the World Trade Organization, has said. Dursun Aydemir—Anadolu/Bloomberg/Getty Images Earlier this week, when the U.S. and EU agreed a five-year ceasefire in a long-running dispute over Boeing and Airbus aircraft subsidies, Okonjo-Iweala tweeted: "With political will, we can solve even the most intractable problems." However, Mercurio is skeptical about her stewardship having much of an effect on the WTO's reform process. "Upon taking [over she] stated it was time for delegations to speak to each other and not simply past each other, but at the recent General Counsel meeting delegations simply read prepared statements in what some have described as the worst meeting ever," he says. "On the other hand, Ngozi is very much someone who will actively seek solutions to problems, and in this way different to her predecessor. If the role of mediator is welcomed, she could have an impact not in starting discussions but in getting deals over the finish line." A spokesperson for the WTO Secretariat declined to offer comment on Mlumbi-Peter and Wallach's suggestions that the organization's credibility rests on the vaccine patent waiver issue, but pointed to a May speech in which Okonjo-Iweala said the WTO could help tackle vaccine supply chain monitoring and transparency, helping manufacturers scale up production, and creating a more geographically diversified manufacturing base. In her speech, the WTO chief also said members "must address issues related to technology transfer, knowhow and intellectual property," including the waiver proposal. "We must act now to get all our ambassadors to the table to negotiate a text," she said.

#### The 1AC evidence isolates that each of the problems they mention aren’t solely caused by IP, but rather expressions of the overarching system of capitalism – thus collapsing the whole system is key.

#### WTO collapse solves extinction

Hilary 15 John Hilary 2015 “Want to know how to really tackle climate change? Pull the plug on the World Trade Organisation” <http://www.independent.co.uk/voices/want-to-know-how-to-really-tackle-climate-change-pull-the-plug-on-the-world-trade-organisation-a6774391.html> (Executive Director, War on Want)//Elmer

Yet this grandiose plan soon fell victim to its own ambition. The WTO’s first summit after the launch of the Doha Round collapsed in acrimonious failure. The next was marked by pitched battles in the streets of Hong Kong as riot police fought Asian farmers desperately trying to save their livelihoods from the WTO’s free trade agenda. The WTO slipped into a coma. Government ministers must decide this week whether to turn off its life support. The answer is surely yes. It was the WTO’s poisonous cocktail of trade expansion and market deregulation that led to the economic crisis of 2008. Years of export-led growth resulted in a crisis of overproduction that could only be sustained with mountains of debt. The parallel deregulation of financial services meant that this debt soon turned out to be toxic, and the world’s banking system went into freefall. Nor is the WTO fit for purpose on ecological grounds. If last week’s climate talks in Paris taught us anything, it is that we must rethink the model of ever-expanding production and consumption in order to avoid planetary meltdown. Global capitalism may need limitless expansion in order to survive, but the planet is already at the very limits of what it can take. The choice is ours. Worst of all, it is the WTO’s ideology of unrestricted trade and corporate domination that lies behind all the bilateral trade deals that are proliferating at the moment, including the infamous Transatlantic Trade and Investment Partnership (TTIP). We need a radically different model of regulated trade and controlled investment if we are to have any chance of breaking the cycle of economic and ecological crisis. For the planet to survive, the WTO must die.

## Case

C1:

CP resolves c1

### Contention 2: Drug Prices

#### Waiving IP enforcement results in rampant increase in counterfeit vaccines – turns case. CP doesn’t link because different offs are different angles that we isolate the affirmative against. Even if CP links we have better solvency w actor

Mercurio 21 (Bryan Mercurio is a Professor and Vice-Chancellor's Outstanding Fellow of the Faculty of Law at the Chinese University of Hong Kong, February 21, 2021, <https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3789820&download=yes>) CS

6. IP enforcement is of vital importance to maintaining safety standards.

The protection of IP not only provides incentives to innovators to create, but also plays a crucial role in ensuring the safety of vaccines and helping to prevent the importation **of fraudulent and dangerous goods**. Unlike the typical pharmaceutical industry, the vaccine market is not a free and open market.69 Vaccines contain biological products made from living organisms and the risk of failure in vaccine development and production is high. 70 Moreover, the manufacturing process for vaccines is much more complex as it requires the use of facilities and equipment with a high degree of specialization.71 The complexity of vaccine products implies that more time and regulatory requirements are needed in order to make or “copy” the vaccine production process. Therefore, the innovator should be expected to make conscious and meticulous decisions as to when and to whom to issue licences, as this is the most responsible way to bring their technologies to the world and safeguard global health.

In addition, as the COVID-19 pandemic continues there has been a **noticeable increase in the circulation of fake medicines** around the world. According to the International Criminal Police Organization (Interpol), **organized crime groups** have been producing fake drugs and medical products and selling them for **lucrative profits in developing countries**.72 With the development of COVID-19 vaccines on the market, a rapid rise in the illegal sale of fake items is expected, according to the United Nations Office on Drugs and Crime (UNODC).73 Counterfeits of the legitimate products provide false promises of protection and could lead to **disastrous consequences**, including **worsened illness and** **death** for the individual and the retardation of herd immunity for the population at large. Effective and proactive **IP** procurement is **essential** and useful in mitigating the risks of counterfeit and substandard medicines. IP enforcement measures play a significant role in preventing these fake and illicit medicines from circulating in the market. While important during normal times, IP enforcement can take on an enhanced role of safeguarding the public during this critical period of time. Waiving all COVID-19 related IPRs raises the risk of unsafe or fake vaccines circulating in supply channels and being sold to unsuspecting governments, **putting millions of human lives at risk** and reducing trust in vaccines.

### Contention 3: Innovation

#### They say no turns but they have no warrants for that, the only card about “Pharmaceutical Lies” is from 2016, don’t assume that nothing has changed in the PAST FIVE YEARS.

#### Link Turn their third contention, their uniqueness is wrong, innovation will be killed by the aff. Our evidence directly contradicts theirs, is three years newer than Mazzucato, **two years newer than** Gubby **AND has better qualifications**

Check this out!

**their card is literally an opinion column on the Washington post, and is from 2018, Our card Swagel 21** is the director of the congressional budget office focusing on R&D in the pharma industry. !

**Their author -> Mariana Mazzucato, 10-17-2018, "Opinion," Washington Post (2018)**

**Our author -> Phillip L. Swagel, Director of the Congressional budget office 4-xx-2021, "Research and Development in the Pharmaceutical Industry," Congressional Budget Office (2021)**

**Glassman directly disagrees with gubby, is two years newer and is from an accredited think tank in europe.**

**Theirs -> Hellen Gubby, professor at the Rotterdam School of Management at Amarus University (2019)**

**Ours -> Executive vice president and a senior fellow at the Center for Global Development, a nonpartisan, nonprofit think tank in Washington and London (2021)**

#### Pharma innovation high now – monetary incentive is the biggest factor.

**Swagel 21** Phillip L. Swagel, Director of the Congressional budget office 4-xx-2021, "Research and Development in the Pharmaceutical Industry," Congressional Budget Office, <https://www.cbo.goc/publication/57126#_idTextAnchor020> SJ//DA

**Every year, the U.S. pharmaceutical industry develops a variety of new drugs that provide valuable medical benefits. Many of those drugs are expensive and contribute to rising health care costs for the private sector and the federal government. Policymakers have considered policies that would lower drug prices and reduce federal drug expenditures. Such policies would probably reduce the industry’s incentive to develop new drugs.** In this report, the Congressional Budget Office assesses trends in spending for drug research and development (R&D) and the introduction of new drugs. CBO also examines factors that determine how much drug companies spend on R&D: expected global revenues from a new drug; cost to develop a new drug; and federal policies that affect the demand for drug therapies, the supply of new drugs, or both. What Are Recent Trends in Pharmaceutical R&D and New Drug Approvals? T**he pharmaceutical industry devoted $83 billion to R&D expenditures in 2019. Those expenditures covered a variety of activities, including discovering and testing new drugs, developing incremental innovations such as product extensions, and clinical testing for safety-monitoring or marketing purposes. That amount is about 10 times what the industry spent per year in the 1980s, after adjusting for the effects of inflation.** The share of revenues that drug companies devote to R&D has also grown: **On average, pharmaceutical companies spent about one-quarter of their revenues (net of expenses and buyer rebates) on R&D expenses** in 2019, which is **almost twice as large a share of revenues as they spent in 2000.** That revenue share is larger than that for other knowledge-based industries, such as semiconductors, technology hardware, and software. The number of new drugs approved each year has also grown over the past decade. On averace, the Food and Drug Administration (FDA) approved 38 new drugs per year from 2010 through 2019 (with a peak of 59 in 2018), which is 60 percent more than the yearly average over the previous decade. **Many of the drugs that have been approved in recent years are “specialty drugs.” Specialty drugs generally treat chronic, complex, or rare conditions, and they may also require special handling or monitoring of patients**. Many specialty drugs are biologics (large-molecule drugs based on living cell lines), **which are costly to develop, hard to imitate, and frequently have high prices.** Previously, most drugs were small-molecule drugs based on chemical compounds. Even while they were under patent, those drugs had lower prices than recent specialty drugs have. Information about the kinds of drugs in current clinical trials indicates that much of the industry’s innovative activity is focused on specialty drugs that would provide new cancer therapies and treatments for nervous-system disorders, such as Alzheimer’s disease and Parkinson’s disease. **What Factors Influence Spending for R&D?** Drug companies’ R&D spending decisions depend on three main factors: Anticipated lifetime global revenues from a new drug, **Expected costs to develop a new drug**, and Policies and programs that influence the supply of and demand for prescription drugs. Various considerations inform companies’ expectations about a drug’s revenue stream, including the anticipated prices it could command in different markets around the world and the expected global sales volume at those prices (given the number of people who might use the drug). The prices and sales volumes of existing drugs provide information about consumers’ and insurance plans’ willingness to pay for drug treatments. Importantly, when drug companies set the prices of a new drug, they do so to maximize future revenues net of manufacturing and distribution costs. A drug’s sunk R&D costs—that is, the costs already incurred in developing that drug—do not influence its price. **Developing new drugs is a costly and uncertain process, and many potential drugs never make it to market. Only about 12 percent of drugs entering clinical trials are ultimately approved for introduction by the FDA. In recent studies, estimates of the average R&D cost per new drug range from less than $1 billion to more than $2 billion per drug**. Those estimates include the costs of both laboratory research and clinical trials of successful new drugs as well as expenditures on drugs that do not make it past the laboratory-development stage, that enter clinical trials but fail in those trials or are withdrawn by the drugmaker for business reasons, or that are not approved by the FDA. Those estimates also include the company’s capital costs—the value of other forgone investments—incurred during the R&D process. Such costs can make up a substantial share of the average total cost of developing a new drug. The development process often takes a decade or more, and during that time the company does not receive a financial return on its investment in developing that drug. The federal government affects R&D decisions in three ways. First, it increases demand for prescription drugs, which encourages new drug development, by fully or partially subsidizing the purchase of prescription drugs through a variety of federal programs (including Medicare and Medicaid) and by providing tax preferences for employment-based health insurance. Second, the federal government increases the supply of new drugs. It funds basic biomedical research that provides a scientific foundation for the development of new drugs by private industry. Additionally, tax credits—both those available to all types of companies and those available to drug companies for developing treatmentscof uncommon diseases—provide incentives to invest in R&D. Similarly, deductions for R&D investment can be used to reduce tax liabilities immediately rather than over the life of that investment. Finally, the patent system and certain statutory provisions that delay FDA approval of generic drugs provide pharmaceutical companies with a period of market exclusivity, when competition is legally restricted. During that time, they can maintain higher prices on a patented product than they otherwise could, which makes new drugs more profitable and thereby increases drug companies’ incentives to invest in R&D. Third, some federal policies affect the number of new drugs by influencing both demand and supply. For example, federal recommendations for specific vaccines increase the demand for those vaccines and provide an incentive for drug companies to develop new ones. Additionally, federal regulatory policies that influence returns on drug R&D can bring about increases or decreases in both the supply of and demand for new drugs. Trends in R&D Spending and New Drug Development Private spending on pharmaceutical R&D and the approval of new drugs have both increased markedly in recent years, resuming a decades-long trend that was interrupted in 2008 as generic versions of some top-selling drugs became available and as the 2007–2009 recession occurred. **In particular, spending on drug R&D increased by nearly 50 percent between 2015 and 2019.** Many of the drugs approved in recent years are high-priced specialty drugs for relatively small numbers of potential patients. By contrast, the top-selling drugs of the 1990s were lower-cost drugs with large patient populations. R&D Spending R&D spending in the pharmaceutical industry covers a variety of activities, including the following: Invention, or research and discovery of new drugs; Development, or clinical testing, preparation and submission of applications for FDA approval, and design of production processes for new drugs; Incremental innovation, including the development of new dosages and delivery mechanisms for existing drugs and the testing of those drugs for additional indications; Product differentiation, or the clinical testing of a new drug against an existing rival drug to show that the new drug is superior; and Safety monitoring, or clinical trials (conducted after a drug has reached the market) that the FDA may require to detect side effects that may not have been observed in shorter trials when the drug was in development. In real terms**, private investment in drug R&D among member firms of the Pharmaceutical Research and Manufacturers of America (PhRMA), an industry trade association, was about $83 billion in 2019, up from about $5 billion in 1980 and $38 billion in 2000**.1 Although those spending totals do not include spending by many smaller drug companies that do not belong to PhRMA, the trend is broadly representative of R&D spending by the industry as a whole.2 A survey of all U.S. pharmaceutical R&D spending (including that of smaller firms) by the National Science Foundation (NSF) reveals similar trends.3 Although total R&D spending by all drug companies has trended upward, small and large firms generally focus on different R&D activities. **Small companies not in PhRMA devote a greater share of their research to developing and testing new drugs,** many of which are ultimately sold to larger firms (see Box 1). By contrast, a greater portion of the R&D spending of larger drug companies (including those in PhRMA) is devoted to conducting clinical trials, developing incremental “line extension” improvements (such as new dosages or delivery systems, or new combinations of two or more existing drugs), and conducting postapproval testing for safety-monitoring or marketing purposes.

#### The aff crushes innovation in the pharma sector---incentivizes them to focus on non-important issues.

Glassman 21 [Amanda; 5/6/21; Executive vice president and a senior fellow at the Center for Global Development, a nonpartisan, nonprofit think tank in Washington and London; “*Big Pharma Is Not the Tobacco Industry*,” Barron, <https://www.barrons.com/articles/big-pharma-is-not-the-tobacco-industry-51620315693>] Justin

But here is the crux of the problem: The pharmaceutical industry is not the tobacco industry. They are not merchants of death. The companies are amoral and exist to make money, but their business is not fundamentally immoral. Big Pharma (mostly) develops and sells products that people need to survive and thrive. Their products improve health and welfare. Fights over access to medicines are possible because medicines exist in the first place—medicines that were usually developed by Big Pharma. And yes, the pharmaceutical industry benefits from public subsidy and publicly financed foundational research. But the companies also put their own capital at risk to develop new products, some of which offer enormous public benefits. In fact, several of them did just that in the pandemic: invested their own money to develop patented manufacturing technologies in record time. Those technologies are literally saving the world right now. Public funding supported research and development, but companies also brought their own proprietary ingenuity and private investments to bear toward solving the world’s singular, collective challenge. Their reward should be astronomical given the insane scale of the health and economic benefits these highly efficacious vaccines produce every day. Market incentives sent a clear signal that further needed innovation—greater efficacy, single doses, more-rapid manufacturing, updated formulations, fast boosters, and others—would be richly rewarded. Market incentives could also have been used to lubricate supply lines and buy vaccines on behalf of the entire world; with enough money, incredible things can happen. But activist lobbying to waive patents—a move the Biden administration endorsed yesterday—sends exactly the opposite signal. It says that the most important, valuable innovations will be penalized, not rewarded. It tells innovators, don’t bother attacking the most important global problems; instead, throw your investment dollars at the next treatment for erectile disfunction, which will surely earn you a steady return with far less agita. It is worth going back to first principles. What problem are we trying to solve? We have highly efficacious vaccines that we would like to get out to the entire world as quickly as possible to minimize, preventable disease and deaths address atrocious inequities, and enable the reopening of society, trade, and commerce. Hundreds of millions of people have been plunged into poverty over the past year; in the developing world, the pandemic is just getting started. What is the quickest way to get this done? Vaccine manufacturing is not just a recipe; if you attack and undermine the companies that have the know-how, do you really expect they’ll be eager to help you set up manufacturing elsewhere? Is the plan to march into Pfizer and force its staff to redeploy to Costa Rica to build a new factory? Do the U.S. administration or activists care that this decision could take years to negotiate at the World Trade Organization, and will likely be litigated for years thereafter? Does it make sense to eliminate the incentive for private companies to invest in vaccine R&D or in the response to the next health emergency? And if the patent waiver is only temporary and building a factory takes months or years, will anyone bother to do so, even if they could? No, none of it makes sense. Worse still, we could solve the policy problem more easily by harnessing market incentives for the global good by ponying up cash to vaccinate the entire world. No confiscation necessary.

**Strong IP protection spurs innovation by encouraging risk-taking and incentivizing knowledge sharing -- prefer statistical analysis of multiple studies**

**Ezell and Cory 19** [Stephen Ezell, vice president & global innovation policy @ ITIF, BS Georgetown School of Foreign Service. Nigel Cory, associate director covering trade policy @ ITIF, MA public policy @ Georgetown. "The Way Forward for Intellectual Property Internationally," Information Technology & Innovation Foundation, 4-25-2019, accessed 8-25-2021, https://itif.org/publications/2019/04/25/way-forward-intellectual-property-internationally] HWIC

IPRs Strengthen Innovation

Intellectual property rights power innovation. For instance, analyzing the level of intellectual property protections (via the World Economic Forum’s Global Competitiveness reports) and creative outputs (via the Global Innovation Index) shows that counties with stronger IP protection have more creative outputs (in terms of intangible assets and creative goods and services in a nation’s media, printing and publishing, and entertainment industries, including online), even at varying levels of development.46

IPR reforms also introduce strong incentives for domestic innovation. Sherwood, using case studies from 18 developing countries, concluded that poor provision of intellectual property rights deters local innovation and risk-taking.47 In contrast, IPR reform has been associated with increased innovative activity, as measured by domestic patent filings, albeit with some variation across countries and sectors.48 For example, Ryan, in a study of biomedical innovations and patent reform in Brazil, found that patents provided incentives for innovation investments and facilitated the functioning of technology markets.49 Park and Lippoldt also observed that the provision of adequate protection for IPRs can help to stimulate local innovation, in some cases building on the transfer of technologies that provide inputs and spillovers.50 In other words, local innovators are introduced to technologies first through the technology transfer that takes place in an environment wherein protection of IPRs is assured; then, they may build on those ideas to create an evolved product or develop alternate approaches (i.e., to innovate). Related research finds that trade in technology—through channels including imports, foreign direct investment, and technology licensing—improves the quality of developing-country innovation by increasing the pool of ideas and efficiency of innovation by encouraging the division of innovative labor and specialization.51 However, Maskus notes that without protection from potential abuse of their newly developed technologies, foreign enterprises may be less willing to reveal technical information associated with their innovations.52 The protection of patents and trade secrets provides necessary legal assurances for firms wishing to reveal proprietary characteristics of technologies to subsidiaries and licensees via contracts. Counties with stronger IP protection have more creative outputs (in terms of intangible assets and creative goods and services in a nation’s media, printing and publishing, and entertainment industries, including online), even at varying levels of development. The relationship between IPR rights and innovation can also be seen in studies of how the introduction of stronger IPR laws, with regard to patents, copyrights, and trademarks, affect R&D activity in an economy. Studies by Varsakelis and by Kanwar and Evenson found that R&D to GDP ratios are positively related to the strength of patent rights, and are conditional on other factors.53 Cavazos Cepeda et al. found a positive influence of IPRs on the level of R&D in an economy, with each 1 percent increase in the level of protection of IPRs in an economy (as measured by improvements to a country’s score in the Patent Rights Index) equating to, on average, a 0.7 percent increase in the domestic level of R&D.54 Likewise, a 1 percent increase in copyright protection was associated with a 3.3 percent increase in domestic R&D. Similarly, when trademark protection increased by 1 percent, there was an associated R&D increase of 1.4 percent. As the authors concluded, “Increases in the protection of the IPRs carried economic benefits in the form of higher inflows of FDI, and increases in the levels of both domestically conducted R&D and service imports as measured by licensing fees.”55 As Jackson summarized, regarding the relationship between IPR reform and both innovation and R&D, and FDI, “In addition to spurring domestic innovation, strong intellectual property rights can increase incentives for foreign direct investment which in turn also leads to economic growth.”56

#### THAT MEANS WE GET THE IMPACT OF THEIR ENGELHARDT EVIDENCE because THEY ACTUALLY CAUSE THIS IMPACT TO HAPPEN THEY READ THIS IN THEIR AFF WE ARE NOT RE-READING IT, THIS IS A TURN

Engelhardt 8, H. Tristram. Innovation and the pharmaceutical industry: critical reflections on the virtues of profit. M & M Scrivener Press, 2008 (doctorate in philosophy (University of Texas at Austin), M.D. (Tulane University), professor of philosophy (Rice University), and professor emeritus at Baylor College of Medicine)

Many are suspicious of, or indeed jealous of, the good fortune of others. Even when profit is gained in the market without fraud and with the consent of all buying and selling goods and services, there is a sense on the part of some that something is wrong if considerable profit is secured. There is even a sense that good fortune in the market, especially if it is very good fortune, is unfair. One might think of such rhetorically disparaging terms as "wind-fall profits". There is also a suspicion of the pursuit of profit because it is often embraced not just because of the material benefits it sought, but because of the hierarchical satisfaction of being more affluent than others. The pursuit of profit in the pharmaceutical and medical-device industries is tor many in particular morally dubious because it is acquired from those who have the bad fortune to be diseased or disabled. Although the suspicion of profit is not well-founded, this suspicion is a major moral and public-policy challenge. Profit in the market for the pharmaceutical and medical-device industries is to be celebrated. This is the case, in that if one is of the view (1) that the presence of additional resources for research and development spurs innovation in the development of pharmaceuticals and med-ical devices (i.e., if one is of the view that the allure of **profit is one of the most effective ways not only to acquire resources but productively to direct human energies** in their use), (2) that given the limits of altruism and of the willingness of persons to be taxed, the possibility of profits is necessary to secure such resources, (3) that the allure of profits also tends to enhance the creative use of available resources in the pursuit of phar-maceutical and medical-device innovation, and (4) if one judges it to be the case that such innovation is both necessary to maintain the human species in an ever-changing and always dangerous environment in which new microbial and other threats may at any time emerge to threaten human well-being, if not survival (i.e., that such innovation is necessary to prevent increases in morbidity and mortality risks), as well as (5) in order generally to decrease morbidity and mortality risks in the future, it then follows (6) that one should be concerned regarding any policies that decrease the amount of resources and energies available to encourage such innovation. One should indeed be of the view that the possibilities for profit, all things being equal, should be highest in the pharmaceutical and medical-device industries. Yet, there is a suspicion regarding the pursuit of profit in medicine and especially in the pharmaceutical and medical-device industries.